Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free DRMAW Stock Alerts

Dermata Therapeutics (DRMAW) Competitors

Dermata Therapeutics logo
$0.01 0.00 (-2.90%)
As of 06/2/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DRMAW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Dermata Therapeutics stock or one of its competitors? MarketBeat compares Dermata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dermata Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Dermata Therapeutics compare to Ainos?

Dermata Therapeutics (NASDAQ:DRMAW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Ainos had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 2 mentions for Ainos and 1 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 1.87 beat Ainos' score of 0.62 indicating that Dermata Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Dermata Therapeutics Very Positive
Ainos Positive

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

Summary

Ainos beats Dermata Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Dermata Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Alvotech and Alvotech both had 1 articles in the media. Dermata Therapeutics' average media sentiment score of 1.87 beat Alvotech's score of 1.44 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
Dermata Therapeutics Very Positive

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$586.32MN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Summary

Alvotech and Dermata Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

How does Dermata Therapeutics compare to Aravive?

Dermata Therapeutics (NASDAQ:DRMAW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, Dermata Therapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for Aravive. Dermata Therapeutics' average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Dermata Therapeutics Very Positive
Aravive Neutral

Summary

Dermata Therapeutics and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Dermata Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Dermata Therapeutics (NASDAQ:DRMAW) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

In the previous week, Dermata Therapeutics had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Dermata Therapeutics' average media sentiment score of 1.87 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Dermata Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

Summary

Dermata Therapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Dermata Therapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Dermata Therapeutics' average media sentiment score of 1.87 beat Biofrontera's score of 0.43 indicating that Dermata Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Dermata Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

Summary

Biofrontera and Dermata Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRMAW vs. The Competition

Export
MetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$456.34M$6.45B$12.42B
Dividend YieldN/A3.87%2.69%5.29%
P/E RatioN/A3.1622.3024.19
Price / SalesN/A6,509.16581.44138.36
Price / CashN/A13.1342.3157.88
Price / BookN/A84.759.846.72
Net IncomeN/A-$96.07M$3.57B$337.19M
7 Day PerformanceN/A-0.06%-1.16%0.48%
1 Month PerformanceN/A0.75%3.85%5.07%
1 Year PerformanceN/A74.31%27.40%34.25%

Dermata Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRMAW
Dermata Therapeutics
N/A$0.01
-2.9%		N/A-4.8%$0.00N/AN/A8
AIMDW
Ainos
N/A$0.13
+116.7%		N/A-15.3%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.18
-5.1%		N/A-93.4%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/A-86.1%$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DRMAW) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel